Drug reference
belzutifan
HIF-2α inhibitor · Antineoplastic agent
HIF-2α inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
D
FDA category + note
Mechanism
Belzutifan is an orally bioavailable inhibitor of HIF-2α. It binds to HIF-2α and blocks its heterodimerization with HIF-1β and activation of target genes.
Indications
von Hippel-Lindau (VHL) disease and associated RCCCNS hemangioblastomaspancreatic NETVHL-associated renal cell carcinoma
Pharmacokinetics
Half-life
14 h (elimination)
Metabolism
UGT2B17 and CYP2C19 (primarily), CYP3A4 (to a lesser extent)
Side effects
Common
anemiafatigueheadachedizziness
Pregnancy & lactation
Pregnancy
D
Related guidelines
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Coronary angiography with renal dysfunction
CSI · Cardiology · 2020
Coeliac disease
OTHER · Gastroenterology · 2016
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Diabetes management in chronic kidney disease
KDIGO · Nephrology · 2022
Ask House about belzutifan
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team